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ABSTRACT
We investigated the potential of arginine to reverse pathological
changes in alcohol-induced liver injury. Four groups (six rats/
group) of male Wistar rats were fed a fish oil-ethanol diet for 6
(group 2) or 8 (group 1) weeks. Rats in group 3 were fed fish
oil-ethanol for 6 weeks, after which they were administered
arginine with fish oil-ethanol for an additional 2 weeks. Rats in
group 4 were fed fish oil-dextrose for 8 weeks. Liver samples
were analyzed for histopathology, lipid peroxidation, cyto-
chrome P4502E1 activity, nuclear factor-B, and levels of mes-
senger RNA for tumor necrosis factor-, cyclooxygenase-2,
and inducible nitric oxide synthase. Concentrations of endo-
toxin were measured in plasma. The most severe inflammation
and fibrosis was detected in groups 1 and 2, as were the
highest levels of endotoxin, lipid peroxidation, cytochrome
P450 2E1 activity, activation of nuclear factor-B, and mRNA
levels for tumor necrosis factor-, cyclooxygenase-2, and in-
ducible nitric oxide synthase. Plasma nitric oxide was also
increased as was nitrotyrosine in liver. After arginine was ad-
ministered, there was marked improvement in the pathological
changes accompanied by decreased levels of endotoxin, lipid
peroxidation, activation of nuclear factor-B, tumor necrosis
factor-, cyclooxygenase-2, inducible nitric oxide, and nitroty-
rosine staining. The therapeutic effects of arginine are probably
secondary to increased levels of nitric oxide but other effects of
arginine cannot be excluded.
Treatment of alcoholic liver disease remains based on nu-
tritional supplements, which include vitamins and trace el-
ements (Fulton and McCullough, 1998; Muller et al., 1998).
The role of specific pharmacological therapy remains un-
proven. One of the mechanisms evoked to explain alcoholic
liver injury is a decrease in oxygen supply that leads to
centrilobular hypoxia. (Videla et al., 1973; French et al.,
1984; Tsukamoto and Xi, 1989). Nitric oxide has been pro-
posed as one of the modulators of regional blood flow to the
liver in various liver diseases (Li and Billiar, 1999). Nitric
oxide also acts as an antioxidant (Joshi et al., 1999). We and
others have shown that enhanced oxidant stress is associated
with pathological changes in alcoholic liver injury (Ceder-
baum 1989; Reinke et al., 1990; Nanji et al., 1994). We have
also previously shown that decreased nitric oxide production
by nonparenchymal cells in the liver is associated with in-
creased severity of liver injury in alcohol-fed rats (Nanji et
al., 1995a). In those experiments, an inhibitor of nitric oxide
production exacerbated alcoholic liver injury, whereas argi-
nine, a substrate for NO, markedly attenuated the patholog-
ical changes.
We tested the hypothesis in the current study that treat-
ment with arginine is able to reverse alcoholic liver injury
even when ethanol administration was continued. The
present set of experiments was designed to simulate the
clinical condition in the outpatient setting in which the pa-
tient continues to drink even after alcoholic liver injury is
present. At the level of the mechanism of alcohol-induced
liver injury, we have proposed that elevated levels of endo-
toxin and lipid peroxides activate nuclear factor-B and lead
to the induction of tumor necrosis factor, cyclooxygenase-2,
and other pro-inflammatory cytokines (Nanji et al., 1997,
1999). We tested the idea in the current work that treatment
with arginine, leads to improvement in liver pathology to-
gether with down-regulation of the above specific pathophys-
iological events.
To evaluate the affect of arginine on alcoholic liver injury,
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we used the intragastric feeding rat model (French et al.,
1986; Tsukamoto et al., 1990). This model shows the patho-
logical changes characteristic of alcoholic liver disease and
allows the correlation between biochemical and pathological
changes.
Materials and Methods
Animal Model and Treatment Groups. Four groups of male
Wistar rats (six rats/group) weighing between 250 and 275 g were
studied to evaluate the effects of arginine on the pathological and
biochemical parameters in ethanol-fed rats. The rats were fed a
liquid diet by continuous infusion through permanently implanted
gastric tubes as described previously (French et al., 1986; Tsukamoto
et al., 1990). The liquid diet contained fish oil as the source of dietary
fat. The amount of ethanol administered was modified to maintain a
blood level of ethanol between 150 and 350 mg/dl. The amount of
ethanol was initially 10 g/kg/day and increased to 16 g/kg/day as
tolerance developed. Each ethanol-fed rat had at least two measure-
ments of blood alcohol. The experimental design is shown schemat-
ically in Fig. 1. Rats in group 1 were fed a fish oil-ethanol (FE) diet
for 8 weeks and then killed; rats in group 2 were fed the fish
oil-ethanol diet for 6 weeks and then killed. Rats in group 3 were fed
the fish oil-ethanol diet for 6 weeks and then administered L-arginine
(100 mg/kg of body weight/day) via intragastric tube for 2 weeks. The
fish oil-ethanol diet was continued for this 2-week period during
which arginine was administered. Rats in group 4 received fish-oil
dextrose for 8 weeks. When the animals were killed, a sample of liver
was obtained for histopathological analysis, and the remainder of the
liver was rapidly excised, washed with ice-cold potassium chloride,
and cut into small pieces that were transferred to plastic vials and
placed in liquid nitrogen. The vials were stored at 80°C.
Histopathological Analysis Including Sirius Red Staining
for Collagen. A small sample of liver was obtained and formalin-
fixed when the rats were killed. Hematoxylin and eosin stain was
used for light microscopy. The severity of liver pathology was as-
sessed as follows: steatosis (the percentage of liver cells containing
fat), 1, 25%; 2, 26 to 50%; 3, 51 to 75%; and 4, 75% of cells
containing fat. Necrosis was quantified as the number of necrotic foci
per square millimeter; and inflammation was scored as the number
of inflammatory cells per square millimeter. At least three different
sections were examined per sample of liver. The pathologist evalu-
ating these sections was unaware of the treatment the rats had
received.
For evaluation of fibrosis around the central veins, sections were
stained with Sirius red and analyzed using computerized image
analysis. The area of collagen deposition around each central vein
was measured using a Macintosh-based morphometric analysis sys-
tem (Apple Computer Inc., Brea, CA) with NIH Image version 1.52
software. The cross-sectional area of the central vein lumen was
measured using the same technique. The area of collagen deposition
was divided by the area of the central vein lumen to correct for the
size of the lumen and provide a standardized measurement of central
vein collagen. The coefficient of variation was determined by assess-
ment of a single central vein on six occasions (5%). Pericellular
fibrosis was estimated as the number of positively staining sites on
adjacent hepatocyte surfaces per 100 hepatocytes around the central
vein.
Immunohistochemistry for Nitrotyrosine. Sections of liver
tissue were immunostained with antiserum to nitrotyrosine. Sec-
tions were deparaffinized in xylene and rehydrated through graded
ethanol concentrations. To block endogenous peroxidase activity, the
sections were immersed in 3% hydrogen peroxide for 5 min at room
temperature. The sections were then stained with antibody to nitro-
tyrosine (Upstate Biotechnology, Lake Placid, NY). Positive staining
was indicated by a brown color generated with diaminobenzidine.
Control sections were incubated with normal rabbit IgG.
Measurement of Blood Alcohol Levels. Blood was collected
from the tail vein, and ethanol concentration was measured using
the alcohol dehydrogenase kit from Sigma Chemical (St. Louis, MO).
Blood was obtained at killing and at other times during the ethanol
feeding period.
Measurement of Plasma Endotoxin Levels. Blood samples
were collected in endotoxin-free vials (Sigma Chemical) and centri-
fuged at 400g for 15 min at 4°C. Samples were then diluted 1:10 in
pyrogen-free water and heated to 75°C for 30 min to remove inhib-
itors of endotoxin from plasma. The limulus amoebocyte lysate test
(Kinetic-QLC; Whittaker Bioproducts, Walkerville, MD) was used
for measurements of endotoxin. Samples were incubated at 37°C for
10 min with limulus amoebocyte lysate. The substrate solution was
added, and the incubation continued for 20 min. The reaction was
stopped with 25% acetic acid. Samples were read spectrophotometri-
cally at 410 nm.
Measurement of Nitric Oxide in Plasma. Nitric oxide in
plasma was measured as previously described (Nanji et al., 1995a).
Briefly, nitric oxide was generated from the nitrite and nitrate an-
ions. The nitric oxide reacted with machine-generated ozone to form
nitrogen dioxide, which generated light at 6500 to 8000 Å. The
amount of light generated was concentration-dependent and was
measured with a photomultiplier tube.
Determination of Thiobarbituric Acid-Reaction Sub-
stances and Conjugated Dienes. Levels of liver thiobarbituric
acid-reactive substances were measured according to the method of
Ohkawa et al. (1997). Conjugated dienes in the total lipid extracted
from liver homogenates were quantified by measurements of optical
density between 220 and 300 nm as described by Recknagel and
Glende (1984).
Preparation of Liver Microsomes and Measurement of 4-Ni-
trophenol Hydroxylase Activity. The microsomal fraction was
prepared as previously described (Nanji et al., 1995b). The term
“microsomal fraction” was applied to the 100,000g particulate frac-
tion derived from liver homogenates by differential centrifugation.
The subcellular fraction was stored at 80°C until use. 4-Nitrophe-
nol hydroxylase activity was determined as previously described
(Koop, 1986).
Determination of Nuclear Factor-B and IKB. Fraction-
ation of the livers into cytosolic and nuclear extracts was as previ-
ously published (Nanji et al., 1999). Nuclear factor-B (NF-B) bind-
ing was determined by electromobility shift assay as described
previously (Nanji et al., 1999). Briefly, equal amounts of nuclear
extracts were incubated with 32P-labeled NF-B oligonucleotide, and
the DNA-protein complexes were separated on polyacrylamide gel.
Specificity of NF-B binding was verified by competition assays and
the ability of specific antibodies to supershift protein-DNA com-
plexes. In the competition assay, a 100-fold excess of the unlabeled
oligonucleotide was used; in the supershift assay, antiserum against
the p50 submit of NF-B was used. Scanning densitometry was used
to quantitate the degree of NF-B activation.Fig. 1. Schematic of the experimental design.
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Western blot analysis was done using antibody against IKB
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) as previously de-
scribed (Nanji et al., 1999). The antibody-reactive bands were visu-
alized by use of enhanced chemiluminescence assay (PerkinElmer
Life Sciences, Boston, MA).
RNA Extraction and Analysis of mRNAs for Cyclooxygen-
ase-1 and -2, Tumor Necrosis Factor-, Inducible Nitric Oxide
Synthase, and -Actin by Reverse Transcription Polymerase
Reaction. To examine the expression of the above mRNAs in liver,
total RNA was extracted according to the guanidinium isothiocya-
nate method (Chomczynski and Sacchi, 1997). The transcription into
complementary DNA and amplification was carried out as previously
described. The sequences of the primer pairs have been reported
previously (Nanji et al., 1997). The gels were analyzed by laser
scanning densitometry as previously described (Nanji et al., 1997).
Statistical Analysis. All data are expressed as means  S.D.
unless otherwise indicated. Differences between groups were ana-
lyzed using analysis of variance or Student’s t test as appropriate.
Results
There was no significant difference in weight gain before
administration of the diet containing arginine (Table 1).
Blood alcohol levels ranged between 150 and 410 mg/dl and
were similar among the groups (Table 1).
Effect of Arginine on Liver Pathology. Feeding a FE
diet for 6 (group 2) or 8 weeks (group 1) caused fatty liver,
necrosis, and inflammation (Table 2; Fig. 2). Control animals
fed fish oil-dextrose (group 4) showed no pathological
changes (Fig. 2). Arginine administration led to a significant
improvement in pathological changes; there was a decrease
in the degree of fatty liver, necrosis, and inflammation (Table
2; Fig. 2). Arginine administration also led to a decrease in
the amount of central vein collagen and pericellular fibrosis
(Figs. 2 and 3).
Modulation of Endotoxin and Lipid Peroxidation.
The effect of arginine on the known mediators of alcohol-
induced lives injury, i.e., endotoxin and lipid peroxidation,
was evaluated at the completion of administration of the
experimental diets. Concentrations of endotoxin were signif-
icantly decreased (p  0.01) after institution of the arginine-
containing diet. (Table 3). Similarly, levels of conjugated
dienes and thiobarbituric acid-reactive substances were sig-
nificantly decreased (p 0.01) after arginine administration.
Part of the explanation for the arginine-induced decrease in
lipid peroxidation could be the decrease in cytochrome P450
2E1 activity (Table 3). Levels of endotoxin, conjugated
dienes, and thiobarbituric acid were not different among rats
fed ethanol and fish oil for 6 or 8 weeks.
Effect of Arginine on Activation of NF-KB. To evalu-
ate the effect of arginine on activation of nuclear factor-B,
electrophoretic mobility shift assays of nuclear extracts from
whole liver were carried out. Nuclear localization of nuclear
factor-B was increased in the fish oil-ethanol-fed groups
(Fig. 4; Table 4). Activation was decreased in the arginine-fed
group. To determine whether activation of nuclear factor-B
was a result of degradation of IKB, IKB was evaluated by
Western blot analysis. In livers from rats fed fish oil-ethanol,
IKB was either absent or markedly decreased (Fig. 4; Table
4). IKB levels were higher in the arginine-treated group
compared with the fish oil-ethanol groups (Table 4).
The protein/DNA complex was further characterized by
competition and supershift assays as previously described
(Nanji et al., 1999). Briefly, antibodies against p50 used in
the supershift assay demonstrated the specificity of the band
and excess NF-B oligonucleotide abrogated complex forma-
tion (data not shown).
Effect of Arginine on Tumor Necrosis Factor-, Cy-
clooxygenase-2, and Inducible Nitric Oxide Synthase.
We have previously proposed that lipid peroxidation and
endotoxin activate nuclear factor-B, which leads to induc-
tion of tumor necrosis factor-, cyclooxygenase-2, and induc-
ible nitric oxide synthase in alcoholic liver injury. Because
the mRNA levels of the above are too low to be detected by
Northern or ribonuclease protection assays, we used RT-PCR
for mRNA analysis. We confirmed that mRNA levels of tumor
necrosis factor-, cyclooxygenase-2, and inducible nitric ox-
ide synthase are up-regulated in fish oil-ethanol-fed rats.
Arginine supplementation led to down-regulation of all three
mRNAs. Cyclooxygenase-1, the constitutive isoform of cyclo-
oxygenase, was similar in all groups (Table 4).
Effect of Arginine on Plasma Nitric Oxide and Liver
Nitrotyrosine. Ethanol administration significantly in-
creased the levels of nitric oxide in plasma (Table 3). In the
ethanol-fed group treated with arginine, the nitric oxide lev-
els were significantly lower (p 0.05) than in the ethanol-fed
groups (groups 1 and 2) but higher than in the dextrose-fed
control group (p  0.05). Intense nitrotyrosine labeling was
observed in the livers of ethanol-fed rats (Fig. 5), in contrast,
much less nitrotyrosine was detected in the arginine-treated
and in the dextrose-fed rats (Fig. 5).
Discussion
Relationship between the Current Experimental
Model and Alcoholic Livers Disease in Humans. The
major problem in treatment of alcoholic liver disease in hu-
mans remains the adherence of patients to abstinence from
alcohol. Many studies have been carried out to determine the
effectiveness of therapy in reducing the progression of liver
injury in alcoholics (reviewed in Fulton and McCullough,
1998). The current data are important in this regard because
the experimental model used has striking resemblance to the
clinical setting in which alcoholic liver disease occurs. The
rats in the present experiments had, similar to the patient
with alcoholic liver disease, manifestations of liver injury
prior to the application of a therapeutic regime. This method
of therapy is in contrast to our previous studies that simu-
lated an in-hospital model where alcohol was discontinued
prior to administration of therapy (Nanji et al., 1995b, 1996).
The current data show that administration of arginine, even
TABLE 1
Blood alcohol levels and weight gain before and after arginine
administration
Experimental Group
Blood
Alcohol
Level
Weight Gain
Before
Arginine
After
Arginine
mg/dl g
FE, 8 weeks 246  51 68  11
FE, 6 weeks 231  46 53  8
FE-arginine, 8 weeksa 260  53 56  10 28  7
FD, 8 weeks 0 77  8
FD, rats fed fish oil and dextrose.
a The 8-week period includes 6 weeks of ethanol and liquid diet followed by
administration of arginine and ethanol for 2 additional weeks.
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when ethanol administration was continued, reduced the
indices of liver pathology, which included fatty liver, necro-
sis, inflammation, and fibrosis.
Mechanisms by Which Arginine Down-Regulates
Pathological Events Triggered by Ethanol. Levels of
endotoxin and lipid peroxides increase in alcohol-induced
liver injury and are believed to be responsible for the hepa-
totoxic effects of alcohol. (Cederbaum, 1989; Nanji et al.,
1993, 1994; Reinke et al., 1990; Adachi et al., 1995). The
observed differences in liver pathology in the rats fed fish
oil-ethanol and those given arginine can be explained, at
least in part, by differences in levels of endotoxin and lipid
peroxides. Animals treated with arginine had an approxi-
mately 50% decrease in the levels of endotoxin and lipid
peroxidation compared with those fed fish oil-ethanol. (Table
3). The mechanisms leading to endotoxemia in ethanol-fed
rats included a reduction in the capacity of Kupffer cells to
detoxify endotoxin and increased permeability of the intesti-
nal mucosa to endotoxin (Nanji et al., 1993). The reduction in
endotoxin levels in arginine-treated rats is probably related
to the improvement in liver function; arginine, to the best of
our knowledge has no effect on the permeability of the gut to
TABLE 2
Severity of pathologic changes in the treatment groups
Treatment Group Duration ofFeeding
Fatty Liver
(0–4) Necrosis Inflammation
weeks foci/mm2 cells/mm2
Group 1
FE, 8 weeks 8 4.0  0.0 1.1  0.4 26.2  7.8
Group 2
FE, 6 weeks 6 4.0  0.0 1.0  0.4 25.8  .4
Group 3
FE-arginine
Fish oil-ethanol 6 4.0  0.0 0.9  0.2 29.1  8.7
Fish oil-ethanol  arginine 2 1.8  0.6a,b 0.3  0.1a,b 9.1  2.4a,b
Group 4
FD, 8 weeks 8 0b 0b 0.2  0.1b
a p  0.01 vs. fish oil-ethanol in the same group (group 3).
b p  0.01 vs. fish oil-ethanol in groups 1 and 2.
Fig. 2. A, liver from a rat fed fish oil-ethanol for 6 weeks showing the presence of fatty liver, necrosis, and inflammation (hematoxylin and eosin, 155
magnification). B, liver from a rat fed fish oil-ethanol for 6 weeks followed by fish oil-ethanol-arginine for 2 weeks. Note the reduction in the degree
of fatty liver, necrosis, and inflammation (hematoxylin and eosin, 155 magnification). C, liver section from a rat fed fish oil-ethanol for 6 weeks and
stained with Sirius red. The connective tissue component of the central vein and cellular fibrosis are increased (magnification, 400). D, liver section
from a rat treated with fish oil-ethanol-arginine for 2 weeks after 6 weeks of fish oil-ethanol administration. Collagen deposition and pericellular
fibrosis are markedly decreased compared with fish oil-ethanol-fed rats.
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endotoxin. The differences in lipid peroxidation could reflect
changes in the activity of cytochrome P450 2E1, which de-
creased about 50 to 60% with arginine administration (Table
3). Cytochrome P450 2E1 is a major contributor to lipid
peroxidation in ethanol-fed rats, and its inhibition leads to a
decrease in the level of lipid peroxidation in the livers of
ethanol-fed rats (Morimoto et al., 1995).
The mechanism for the decrease in cytochrome P450 2E1
activity with arginine is likely related to the effect of inhibi-
tion of the enzyme activity by nitric oxide. Nitric oxide is
generated from arginine and reacts with CYP 2E1 and inhib-
its its activity and generation of free radicals (Gergel et al.,
1997; Khatsenko, 1998).
Arginine-Induced Down-Regulation of Nuclear Fac-
tor-B, Tumor Necrosis Factor-, Cyclooxygenase-2,
and Inducible Nitric Oxide Synthase. One pathway by
which endotoxin and lipid peroxidation promote alcoholic
liver injury is via activation of nuclear factor-B, a ubiqui-
tous transcription factor that activates many inflammatory
genes. Our data confirm our previous observation that acti-
vation of nuclear factor-B occurs in association with necro-
inflammatory changes in fish oil-ethanol-fed rats (Nanji et
al., 1999). The decrease in the degree of nuclear factor-B
activation by arginine was accompanied by down-regulation
Fig. 3. Changes in the amounts of collagen and pericellular fibrosis in
rats fed FE for 6 weeks followed by fish oil-ethanol-arginine (FE-A) for 2
weeks. The results of the biopsy at 6 weeks served as a baseline for
comparison with the results after treatment with arginine. In the argin-
ine-treated animals, the amount of central vein collagen (% area) de-
creased from 1.5 0.2% to 0.6 0.1% (p 0.01). Pericellular fibrosis was
also decreased from 21  5 to 11  3 (p  0.05). The amount of collagen
and pericellular fibrosis was not significantly different in the liver biop-
sies obtained after 6 weeks in comparison to values seen in animals fed
fish oil-ethanol for 6 weeks (group 2) or 8 weeks (group 1).
Fig. 4. Representative electrophoretic mobility shift assay for NF-B
activation in nuclear extracts and Western blot analysis for IKB protein
in the cytosolic extracts from livers in the different experimental groups.
Extracts from rats in the FE group showed increased binding activity
(lane 1). Binding activity was decreased in the arginine-treated group
(lane 2) (see also Table 4). Activation of NF-KB was associated with
decreased IKB protein levels in the FE rats, and the level of IKB was
higher in the arginine-treated rats compared with the FE group (Table 4).
A low level of NF-B activation was seen in rats fed fish oil-dextrose (lane
3).
TABLE 3
Measurement of endotoxin, lipid peroxidation, and 4-nitrophenol hydroxylase and nitric oxide in the experimental groups
Experimental Group Endotoxin TBARS ConjugatedDienes A232
4-Nitrophenol
Hydroxylase Nitric Oxide
pg/ml nmol/mg
protein
nmol/min/mg m/l
1) FE, 8 weeks 73  12 1.52  0.36 0.50  0.15 3.2  0.69 110  22
2) FE, 6 weeks 76  14 1.48  0.32 0.46  0.12 3.01  0.57 101  19
3) FE-arginine, 8 weeks 31  8a 0.59  0.14a 0.19  0.09a 1.12  0.13b 63  10b
4) FD, 8 weeks 10  5a,c 0.33  0.11a 0.16  0.07a 1.17  0.16b 34  8b,c
TBARS, thiobarbituric acid-reactive substances.
a p  0.01 vs. groups 1 and 2.
b p  0.05 vs. groups 1 and 2.
c p  0.05 vs. group 3.
TABLE 4
Analysis of NF-B, IB, TNF-, Cox-2, and Cox-1 in the different experimental groups
Experimental
Group NF-B IB-
TNF-
mRNA
Cox-2
mRNA
iNOS
mRNA
Cox-1
mRNA
relative units relative to -Actin
1) FE, 8 weeks 6.4  1.8 0.17  0.09 7.2  2.8 1.4  0.6 4.8  1.1 1.0  0.1
2) FE, 6 weeks 5.3  2.1 0.21  0.06 6.9  1.9 1.3  0.5 4.2  1.4 1.0  0.2
3) FE-arginine 1.4  0.8a 0.46  0.09a 3.0  1.8b 0.4  0.1b 1.1  0.4a 1.2  0.2
4) FD, 8 weeks 1.0a 1.0a 1.0a 0a 0.6  0.2a 1.0
a p  0.01 vs. groups 1 and 2.
b p  0.05 vs. groups 1 and 2.
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of tumor necrosis factor- and cyclooxygenase-2. A growing
body of evidence implicates nuclear factor-B, tumor necrosis
factor-, and cyclooxygenase-2 in inflammatory liver injury
(McClain et al., 1993; Dinchuk et al., 1995; Nanji et al., 1997).
We therefore hypothesize that down-regulation of these pro-
inflammatory stimuli by arginine and possibly nitric oxide
contribute to the improvement in liver pathology.
In the present study, increased levels of mRNA for induc-
ible nitric oxide synthase, nitric oxide, and staining for ni-
trotyrosine were seen in the hepatocytes of ethanol-fed rats.
The increase in nitrotyrosine together with the increase in
iNOS suggests that NO production in hepatocytes and for-
mation of nitrotyrosine are intimately linked. This view is
further supported by the down-regulation of inducible nitric
Fig. 5. Immunohistochemical anal-
ysis of nitrotyrosine in liver speci-
mens obtained from a rat fed fish
oil-ethanol for 6 weeks (A) and fish
oil-ethanol for 6 weeks followed by
fish oil-ethanol-arginine for 2 weeks
(B). An increase in the level of nitro-
tyrosine staining, particularly in
the centrilobular area, was evident
in all rats fed fish oil-ethanol for 6
weeks. A marked decrease in nitro-
tyrosine staining was seen in all of
the arginine-treated rats (B). The
level of staining was similarly low
in fish oil-dextrose-fed rats (data
not shown).
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oxide synthase and nitrotyrosine formation in arginine-
treated rats. The formation of nitrotyrosine depends on the
reaction between NO and superoxide, which yields the pow-
erful oxidant peroxynitrite (Grisham, 2000). The association
between increased levels of lipid peroxidation, iNOS mRNA,
and nitrotyrosine underscores the importance of the interac-
tion between nitric oxide and free radicals in alcoholic liver
injury.
One assumption for the mechanism involved in the protec-
tive effect of arginine in liver injury is that it acts as a
precursor for nitric oxide (Nanji et al., 1995a; Cottart, 1999;
Vallance and Chan, 2001). However, this hypothesis is con-
troversial since the enzyme nitric oxide synthase is saturated
with substrate at physiological levels (Boger and Bode-Boger,
2001). Several explanations have been provided in an at-
tempt to resolve this “arginine paradox” (Boger and Bode-
Boger, 2001). Firstly, because the endothelial isoform of ni-
tric oxide is located in the caveolae, additionally arginine
may be necessary to be fully utilized in this microenviron-
ment (Feron and Kelly, 2001). Secondly, increased arginine
may be required to overcome the inhibitory effects of endog-
enous inhibitors of nitric oxide synthase. Finally, the effect of
arginine could be independently mediated through its vaso-
dilatory and antioxidant effects (Cottart et al., 1999). Addi-
tionally, arginine inhibits inflammation and fibrogenesis
(Boger and Bode-Boger, 2001).
The exact isoform of nitric oxide synthase responsible for
protection against liver toxicity is not known. Studies using
specific nitric oxide synthase inhibitors and knockout models
have yielded divergent results on the role of the individual
isoforms in liver toxicity (Clemens, 1999; Mashimo and
Goyal, 1999). Despite these shortcomings, many of our find-
ings could be ascribed to a protective role for nitric oxide.
Nitric oxide inhibits free radical productions and decreases
inflammatory changes by inhibiting nuclear factor-B activ-
ity (Grisham, 2000). Inhibition of hepatic stellate cell func-
tion and smooth muscle proliferation by nitric oxide may
account for the reversal of fibrosis (Rockey and Chung, 1995;
Failli et al., 2000). Additionally, nitric oxide inhibits cycloox-
ygenase-2 activity causing a reduction in formation of vaso-
active prostanoids (Clancy et al., 2000). Although levels of
nitric oxide in arginine-treated rats were lower than in rats
administered than fish oil-ethanol but still higher than in
control rats, the most likely reason for the potential protec-
tive effect of nitric oxide is related to the site of synthesis.
Nitric oxide production in arginine-supplemented rats is
through endothelial nitric oxide synthase (Cottart et al.,
1999). However, other mechanisms, outlined previously, may
account for improvement in pathologic changes in addition to
the nitric oxide-mediated effects.
In conclusion, our results show that arginine administra-
tion, probably through the generation of nitric oxide, leads to
improvement in pathological changes such as fatty liver,
necrosis, inflammation, and fibrosis. These improvements
were accompanied by down-regulation of nuclear factor-B,
pro-inflammatory cytokines cyclooxygenase-2, and inducible
nitric oxide synthase. It will be important to further charac-
terize the activity of the various nitric oxide synthase iso-
forms in the different cell types in liver in this model to
further clarify the therapeutic role of arginine and other
nitric oxide-donors in alcoholic liver disease. Since nitric
oxide, in addition to having antioxidant effects, can also
behave as a pro-oxidant (Joshi et al., 1999), the amount of
nitric oxide-donor used in the treatment of inflammatory
liver diseases needs to be carefully titrated.
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